Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $291
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Amgen (NASDAQ:AMGN) and lowered the price target from $300 to $291.
November 01, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Amgen and lowered the price target from $300 to $291, which may impact the stock's performance.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the perceived value of Amgen. This could lead to a negative sentiment among investors, potentially causing a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100